Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Imatinib mesylate therapy in CML patients is a generally well tolerated without any significant hematological adverse drug effects. However, complications like anemia and cytopenias have been described in literature. A very few case reports of bone marrow aplasia following imatinib therapy have been reported so far. We here report five patients of CML who developed bone marrow aplasia following imatinib therapy.
Srinivas
Upendra
U
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Pillai
Lakshmi S
LS
Kumar
Rajat
R
Pati
H P
HP
Saxena
Renu
R
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000139:chemically induced*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D001856:Bone Marrow Examination; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate